Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
ViroMissile, Inc.
Seagen Inc.
Essen Biotech
MacroGenics
City of Hope Medical Center
Guerbet
AbbVie
Ocellaris Pharma, Inc.
Mayo Clinic
Mayo Clinic
NeoTX Therapeutics Ltd.
City of Hope Medical Center
Travera Inc
GONGCHU Biotechnology Co., Ltd
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Cancer Research UK
University of Virginia
Incyte Corporation
UNICANCER
AbbVie
Arbeitsgemeinschaft medikamentoese Tumortherapie
Gene Solutions
Sotio Biotech Inc.
Carisma Therapeutics Inc
Tasly Biopharmaceuticals Co., Ltd.
Travera Inc
Salubris Biotherapeutics Inc
Xencor, Inc.
Pliant Therapeutics, Inc.
Exelixis
BioEclipse Therapeutics
Cellestia Biotech AG
Lebanese University
Fate Therapeutics
Centro di Riferimento Oncologico - Aviano
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Jules Bordet Institute
Institut Bergonié
Xencor, Inc.
Provectus Pharmaceuticals
Incyte Corporation